ERGIC2 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 0 bp insertion in exon 2 and 1 bp deletion in exon 2 and Insertion of the selection cassette in exon 2.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 0 bp insertion in exon 2 and 1 bp deletion in exon 2 and Insertion of the selection cassette in exon 2.
Alternative names
CD14 protein, CDA14, ERGI2_HUMAN, ERGIC 2, ERGIC and golgi 2, Endoplasmic reticulum-Golgi intermediate compartment protein 2, Erv41, MGC111152, PTX 1, PTX1 protein, cd002
What's included?
Recommended products
ERGIC2 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 0 bp insertion in exon 2 and 1 bp deletion in exon 2 and Insertion of the selection cassette in exon 2.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 0 bp insertion in exon 2 and 1 bp deletion in exon 2 and Insertion of the selection cassette in exon 2.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- ERGIC2
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
ERGIC2 also known as PTX1 is involved in transport and processing within the endoplasmic reticulum-Golgi intermediate compartment. ERGIC2 has a mass of approximately 45 kDa. It is an integral membrane protein widely expressed in various tissues and particularly prominent in the liver and kidney. This protein plays a significant role in regulating the trafficking of proteins between the endoplasmic reticulum and the Golgi apparatus important for proper cellular function.
- Biological function summary
ERGIC2 contributes to the maintenance of the cellular infrastructure by facilitating the efficient transport of proteins. It is an essential component of the early secretory pathway and plays a role in protein sorting and vesicle formation. ERGIC2 participates in a well-defined protein complex associated with COPII-coated vesicles which aid in cargo transport from the endoplasmic reticulum to the Golgi. Its interaction within this complex highlights its importance in cellular logistics and management.
- Pathways
ERGIC2 participates actively in the ER-Golgi transport pathway and the secretory pathway. These pathways are essential for efficient protein trafficking and processing. ERGIC2 interacts with other proteins such as COPII components including SEC23 and SEC24 which are integral to the formation of transport vesicles. These interactions highlight how ERGIC2 fits into larger pathways that ensure cellular homeostasis and functionality.
- Associated diseases and disorders
Alterations in ERGIC2 expression have been observed in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Insufficient or excess ERGIC2 can impair protein trafficking leading to cellular stress and disease progression. Its role in these disorders bridges it to proteins like APP (Amyloid precursor protein) in Alzheimer's disease potentially affecting amyloid processing and aggregation. Understanding ERGIC2's function may offer insights into therapeutic strategies for these conditions.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell lysate (ab258862)
Allele-3: Insertion of the selection cassette in exon 2
Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell lysate (ab258862)
Allele-1: 1 bp deletion in exon 2
Sanger Sequencing - Human ERGIC2 (PTX1) knockout HeLa cell lysate (ab258862)
Allele-2: 0 bp insertion in exon 2
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com